JPRN-jRCTs051180198进行中（未招募）2 期
A phase II study of systemic chemotherapy with S-1 and oxaliplatin followed by gastrectomy with D2 or D2 plus limited para-aortic lymph node sissection in HER2 negative advanced gastric or esophagogastric junction cancer with extensive lymph node metastasis. - SOX-D2 study
Sano Takeshi0 个研究点目标入组 35 人开始时间: 2019年3月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven gastric adenocarcinoma
- •2) HER2 negative (IHC 0 or IHC 1+, or IHC 2+/FISH -)
- •3) One of the following conditions is fulfilled by enhanced CT
- •1. Paraaortic lymph node metastasis (No.16a2/ 16b1)
- •2. Bulky N (at least one node of 3 cm or more in diameter, or at least three consecutive nodes each of diameter 1.5 cm or more, along the coeliac, splenic, common or proper hepatic arteries or superior mesenteric vein.)
- •3. Both of No.16a2/ 16b1 and bulky lymph node metastasis
- •4. Thoracic/ abdominal/ pelvic enhanced CT reveals none of the following findings:
- •i) Mediastinal lymph node metastasis
- •ii) Lung metastasis
- •iii) Peritoneal metastasis
- •iv) Liver metastasis
- •v) Pleural effusion, ascites beyond the pelvis
- •vi) Paraaortic No. 16a1 or No. 16b2 swelling 1cm or greater
- •vii) Other distant metastases (except for No. 13, No. 16a2 or No. 16b1 metastasis)
- •5) Neither Borrmann type 4 nor large (8cm or more) type 3
- •6) Length of esophageal invasion less than or equal to 3cm
- •7) Not stump cancer of stomach.
- •8) Clinically no sign of distant metastasis
- •9) No liver or peritoneal metastasis and CY0 by laparoscopy or laparotomy for bypass surgery within 28 days before registration
- •10) Age between 20 and 75 at registration
- •11) Performance Status (ECOG) 0 or 1
- •12) No prior chemotherapy, radiotherapy or endocrinotherapy
- •13) No prior surgery for gastric carcinoma except for bypass surgery and endoscopic mucosal resection
- •14) Fair oral intake with or without bypass surgery
- •15) Adequate organ functions defined as indicated below;
- •i) WBC >= 4,000/mm3 and <= 12,000/mm3
- •ii) Neutrophils >= 4,000/mm3
- •iii) Hb >= 8.0 g/dl
- •iv) Platelet >= 100,000/mm3
- •v) AST <= 100IU
- •vi) ALT <= 100IU
- •vii) T.bil <= 1.5 mg/dL
- •viii) Creatinine <= 1.2 mg/dL
- •viii) Ccr >= 60 mL/min/body
- •16) Written informed consent
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal cancer
- •2) Women during pregnancy or breast-feeding
- •3) Severe mental disease
- •4) Under treatment with systemic steroid
- •5) HBs antigen positive
- •6) Under treatment with flucytosine, phenytoin, or warfarin
- •7) Allergy to iodine
- •8) History of hypersensitivity to oxaliplatin or S-1
- •9) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason
- •10) Edema of limbs or trunk by any reason
- •11) Interstitial pneumonia, pulmonary fibrosis or severe emphysema.
- •12) Active bacterial or fungal infection
- •13) Past history of myocardial infarction or unstable angina pectoris within 6 months
- •14) Uncontrollable hypertension
- •15) Uncontrollable diabetes mellitus or routine administration of insulin
研究者
相似试验
已完成
2 期
ESOX trialadenocarcinoma of the esophagogastric junctionJPRN-jRCTs051180192Watanabe Masayuki50
招募中
2 期
A phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in T3/T4a and/or lymph node-positive advanced adenocarcinoma of the esophagogastric junctioJPRN-UMIN000020815Cancer Institute Hospital, Gastroenterological Chemotherapy Department50
已完成
2 期
A phase II study of systemic chemotherapy with S-1 and Oxaliplatin followed by gastrectomy with D2 or D2 plus limited para-aortic lymph node dissection in HER2 negative advanced gastric or esophagogastric junction cancer with extensive lymph node metastasisGastric cancerJPRN-UMIN000027506Cancer Institute Hospital35
已完成
不适用
A phase I/II study of chemotherapy using S-1, Oxaliplatin plus Irinotecan for unresectable pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000014471Department of Gastroenterology Kitasato University School of Medicine25
招募中
2 期
Phase II study of perioperative chemotherapy for cStage II and III thoracic esophageal canceresophageal cancerJPRN-jRCTs051200048Kitadani Junya27